Genmab

	10/11 18:10 af GeorgeBest	He says they can produce thousands of samples in the same time as competitors produce a handful!
	10/11 18:09 af GeorgeBest	Jan always points out Genmabs abilities to combine bispecific antibodies via robotics. Any idea why other Pharma companies can‘t copy?
	10/11 18:06 af AaBforever	@E L What do you expect we will hear on fridag 13.?
	10/11 18:06 af GeorgeBest	But I am sure they will deliver again
	10/11 18:06 af GeorgeBest	Yes, I must admit, I got carried away with Jans words again again...;-)
	10/11 18:02 af E L	but seriously curious what people where expecting/ why they are disapointed. We have seen these sort of early data sets many times before now, it ususally isn't more then this
	10/11 18:00 af E L	I did - and no need to say thanks.
	10/11 17:45 af gdn55	Ditto her. Tak
	10/11 17:34 af GeorgeBest	Thanks E L for the fantastic job you are doing :-)
	10/11 17:16 af E L	what is it then that you where hoping for / expecting?
	10/11 16:35 af Bulder	looks like it, both Q
	10/11 16:31 af E L	should we conclude that Colorectal cancer and Ovarian cancer will not continue to the expansion phase?
	10/11 16:25 af E L	on P20 of the presentation , fig A, the best change in SoD from baseline =-100%; does that mean the tumor disappeared?
	10/11 16:19 af peter12	ok tak ;-)
	10/11 16:15 af Bulder	det er epco Peter
	10/11 16:11 af peter12	And as disclosed in the abstract, by the time of the cut, the median follow-up was 8.3 months, and 25 patients were still ongoing. And I think that with this, I give you a signal, that 25 patients were still ongoing. And if you look at the data again at the tail, in above 48 milligrams for the DLBCL from 7 patients, the ORR was 100%; CR, 28%; 72% PRs, and those patients were ongoing. So – and the FPL, same thing, above 12. And the cut is arbitrary,
	10/11 16:10 af peter12	Judith also mentioned CR's at the cc ?
	10/11 16:06 af E L	2x NSCLC, Urothelial, Endometrial, TNBC (Triple-negative breast cancer), SCCHN ( Squamous Cell Carcinoma of the Head and Neck) and Cervical
	10/11 16:03 af E L	So on my earlier question, will they open expansion cohorts for the other diseases?' there will be 7 expansion cohorts with up to 40 patients per cohort
	10/11 15:17 af DevOp	Thx E L, now with easily read dosing.
	10/11 15:09 af E L	Presentation easier to read as earlier poster (link)
	10/11 15:08 af E L	In the expansion cohort, which includes patients with PD-L1 relapsed/refractory NSCLC, two of 12 patients that could be objectively assessed achieved confirmed single-agent partial responses. One patient had an unconfirmed partial response and four patients demonstrated stable disease. BNT311/GEN1046 is partnered with Genmab. (link)
	10/11 15:08 af E L	No treatment-related bilirubin increases or Grade 4 transaminase elevations were observed. Clinical benefit was observed across tumor types and dose levels, including in patients resistant to prior immunotherapy and with tumor types less sensitive to immune checkpoint inhibitors. Disease control was achieved in 65.6% of patients in the dose escalation portion, including partial responses in one TNBC patient, one ovarian cancer patient and two immune checkpoint inhibitor pre-treated NSCLC patient
	10/11 15:08 af E L	BioNTech: Next-generation checkpoint immunomodulators BNT311 – Interim data from a first-in-human Phase 1/2a trial of BNT311 (PD-L1x4-1BB; Gen1046) in 61 heavily pretreated patients with advanced solid tumors was presented at SITC 2020. In the dose escalation phase, BNT311 demonstrated a manageable safety profile and encouraging early single-agent clinical activity. Most adverse events were mild to moderate and treatment-related Grade 3 transaminase elevations resolved with corticosteroids.

	10/11 15:04 af Bulder	CLL - ofa didn't make it. Let's hope this one goes better.
	10/11 14:58 af Bulder	also at 3 locations in DK. Wonder when we see the ph 3 trial on ct.
	10/11 14:51 af E L	New Epcoritamab trial: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (link)
	10/11 12:52 af Mogan	10/11 11:47 af Mogan @Klarussen, når du skriver, at du genkøber i 2150, er det så for likvider stående på sidelinjen, eller har du solgt på toppen lige inden faldet de sidste dage? Skriver af nysgerrighed, da jeg selv ikke sælger, og tager turen med op og ned.
	10/11 12:50 af Mogan	@Stockbull, Undskyld det var "Klarussen, som skrev det med salg i 2150 - må spørge ham.
	10/11 12:47 af Mogan	@StockBull, når du skriver, at du genkøber i 2150, er det så for likvider stående på sidelinjen, eller har du solgt på toppen lige inden faldet de sidste dage? Skriver af nysgerrighed, da jeg selv ikke sælger, og tager turen med op og ned.
	10/11 12:47 af bikube	Godt set LLI. Det kunne have sparet mig mange penge.
	10/11 12:35 af bikube	Helt korrekt StockBull - den store forskel er om man har købt for 10000 i kurs 25 eller for 10000 i kurs 50, så er det pludselig dobbelt op.
	10/11 12:28 af StockBull	Korrekt. Lad os sige du køber 100 så er forskellen 15.000kr. Profil 785.000 kontra 770.000 så ikke den store forskel i et generelt positivt marked hvor der er risiko for kursen aldrig mere kommer under 2155 :-)
	10/11 12:08 af Klarussen	Kommer an på hvor mange man køber...
	10/11 11:52 af StockBull	M.h.t festen ligger landet sådan, at festen startede i kurs 25 for 10 år siden og mon ikke vi om 10 år ligger pænt over kurs 10.000, så om man køber i 2150 eller 2300 giver ikke den store forskel på den lange bane. Det ville jo også ha været lige næsten lige fedt om man betalte 25 eller 30 kr i 2010
	10/11 11:52 af JørgenVarnæs	Det er noget gætværk med den høje af de to doser - men det er da temmelig umodne data vi kigger på her. Grunden til eufori er på ingen måde væk for mig...
	10/11 11:47 af DevOp	JV, ligner 80 og 200mg. Det kunne godt være en del af årsagen til, at det er NSCLC, der udvides med expansion cohorte først
	10/11 11:46 af StockBull	Derudover kan vi se frem ASH Data Review 8 Dec.
	10/11 11:43 af StockBull	Træet skal rystes inden CMD :-)
	10/11 11:40 af Klarussen	Festen forbi for denne gang. Genkøber i 2150.
	10/11 11:37 af Mcjean	Hvad betyder "advance" i jeres terminologi set i forhold til abstract? Måske det er kodeordet til forståelsen af "knock your socks of". Vi taler om gode data set i forhold til at patienterne er dødsdømte og dette prøves som en mirakelkur. Så ser data jo vildt gode ud vil jeg mene, endda med god bivirkningsprofil og en safety et stykke under limit, men kan være jeg tager fejl. det er bare et gæt ud fra få informationer.
	10/11 11:33 af Mogan	I går var vi nede med ca. 5.3% midt på dagen, men det endte dog "kun" med minus 3%.
	10/11 11:30 af JørgenVarnæs	Hmm - og eftersom der ikke er en 300mg dose, så er det måske mere en 100mg dose?
	10/11 11:27 af JørgenVarnæs	Det er godt spottet ligner det ikke at de 2 PR på NSCLC er hhv 80mg og 300mg?
	10/11 11:27 af Helge Larsen/PI-redaktør	Novo, Bava, Zeal og Gen er ramt i dag.
	10/11 11:25 af E L	i tried @DevOp , maybe i need new spectacles ;-) agree with your 09.54 btw. Judith also mentioned something about that
	10/11 11:24 af AaBforever	Man kan godt blive lidt rundtosset med den fart rotationen har på.
	10/11 11:23 af Helge Larsen/PI-redaktør	Enig Bulder.
	10/11 11:21 af DevOp	E L, if you zoom in the PDF, most of the doses are "readable"
	10/11 11:20 af Bulder	Faldet skyldes ikke disse data. Det er sektorrotationen der fortsætter. Desværre falder det lige sammen med vore forventninger om stigninger op til CMD.